"
Team:UCL/Practice/Report
From 2013.igem.org
| (8 intermediate revisions not shown) | |||
| Line 11: | Line 11: | ||
<script> | <script> | ||
| - | var word1 = " | + | var word1 = "FEAS"; |
| - | var word2 = " | + | var word2 = "ABILITY"; |
</script> | </script> | ||
| Line 46: | Line 46: | ||
<div class="full_page"> | <div class="full_page"> | ||
| - | <div class="main_image" | + | <div class="main_image" style="background-image:url('https://static.igem.org/mediawiki/2013/f/f3/Twobrain.png');"> |
| - | + | ||
| - | + | ||
| - | + | ||
</div> | </div> | ||
| Line 55: | Line 52: | ||
</div> | </div> | ||
| - | <p class="major_title">FEASIBILITY | + | <p class="major_title">FEASIBILITY REPORT</p> |
<p class="minor_title">A Practical Assessment Of Implementing Our Treatment</p> | <p class="minor_title">A Practical Assessment Of Implementing Our Treatment</p> | ||
<p class="body_text"> | <p class="body_text"> | ||
| - | We conducted a feasibility report on how likely it is that our | + | We conducted a feasibility report on how likely it is that our remedy would be accepted by the public and government, and the competitiveness of our remedy, in light of recent <a href="http://www.reuters.com/article/2013/05/07/us-baxter-study-alzheimers-idUSBRE9460E020130507" target="_blank">pharmaceutical failures </a> for <a href="https://2013.igem.org/Team:UCL/Background/Alzheimers" target="_blank">Alzheimer’s Disease (AD)</a>. |
</p> | </p> | ||
| Line 71: | Line 68: | ||
<p class="minor_title">The Report</p> | <p class="minor_title">The Report</p> | ||
<p class="body_text"> | <p class="body_text"> | ||
| - | In this report, team member <a href="https://2013.igem.org/Team:UCL/Team/Profile" target="_blank">Andy Cheng</a> examines the economic feasibility of distributing our proposed treatment, looking at resource allocation, the cost of research for AD and the <a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2526383/" target="_blank">cost-benefit</a> of spending on the ageing population | + | In this report, team member <a href="https://2013.igem.org/Team:UCL/Team/Profile" target="_blank">Andy Cheng</a> examines the economic feasibility of distributing our proposed treatment, looking at resource allocation, the cost of research for AD and the <a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2526383/" target="_blank">cost-benefit</a> of spending on the ageing population. |
</p> | </p> | ||
| + | |||
| + | |||
| + | <div class="gap"></div> | ||
| + | |||
| + | <p class="body_text"><b> <a href="https://2013.igem.org/Team:UCL/Practice/treatmentfeasibility" target="_blank">Feasibility Report: GEM Cell Treatment</a></p> | ||
| + | |||
| + | |||
<div class="gap"></div> | <div class="gap"></div> | ||
Latest revision as of 01:15, 5 October 2013
FEASIBILITY REPORT
A Practical Assessment Of Implementing Our Treatment
We conducted a feasibility report on how likely it is that our remedy would be accepted by the public and government, and the competitiveness of our remedy, in light of recent pharmaceutical failures for Alzheimer’s Disease (AD).
It is clear that a cure for AD is desperately sought after. Using the result of surveys and discussions with medical doctors and carers of patients with AD we concluded that even with the controversy of synthetic biology, if a safe and effective treatment were created, patients, carers, relatives, members of the public would all support our treatment.
Also, we made estimates towards the costs of our proposed treatment and the issues our product has to overcome to be marketable. A high price would mean less people would be able to afford it, however, it is necessary as most innovative technologies start out at a high price but becomes more affordable with time. Furthermore, even at the high price, people would still want to use our treatment (given that it’s proven successful), because no drugs have been deemed cost-effective so far.
The Report
In this report, team member Andy Cheng examines the economic feasibility of distributing our proposed treatment, looking at resource allocation, the cost of research for AD and the cost-benefit of spending on the ageing population.
